With $36m in seed funding under its belt, Peel Therapeutics is harnessing the power of Darwinian science as it advances a pipeline of cancer and anti-inflammation assets inspired by plant and animal kingdoms.
“What we’re doing may sound like science fiction,” Peel Therapeutics CEO and co-founder Joshua Schiffman told In Vivo. Indeed, it is not every day that industry takes inspiration from elephant genes, traditional Chinese medicines and insect venom.
But Schiffman is confident that Peel can “identify the superpowers found in evolutionary biology” and add “solubility, scalability and bioavailability” to develop safe and efficacious medicines. This core belief is...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
